extract9_07/2025_NL-Issue55
…inform and support clinical practice. The third focus is on scientific advice. In the United States, we are often called upon to sit on scientific advisory committees, for example, and… […]
…inform and support clinical practice. The third focus is on scientific advice. In the United States, we are often called upon to sit on scientific advisory committees, for example, and… […]
…COMPARISON OF MODELS FOR ESTIMATING AGE AT MOTOR ONSET IN HD… C07 GENETIC RISK FOR PSYCHIATRIC DISORDERS IS ASSOCIATED WITH PSYCHIATRIC AND COGNITIV… Wet biomarkers D01 TWO INDEPENDENT VALIDATIONS OF… […]
…The conference will consist of a presentation by the sponsor, Roche, followed by a Q&A session and a discussion by a panel on open (and answered) questions and the way… […]
…how long can you vote? The electronic ballot is open from Monday, August 1 until Friday, September 14, 2018. Get to know the candidates Read more about this year’s candidates… […]
…Application of genetic modifier of Huntington’s disease data in the clinical setting: promise, pitfalls & development of a framework. Meeting agenda: PDF Meeting contact: Kristina Becanovic EHDN Lanco, Sweden… […]
…ERN-RND provides free educational webinars on rare neurological and neuromuscular diseases – in collaboration with the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD) and the European Academy of… […]
…more easily find care in their own communities. The popular CME4HD program provided at HSG’s annual event is now available online, anytime, anywhere – for FREE. Find out more… […]
…The MDS-ES and EHDN Joint Online Course Series: Huntington’s Disease: From Foundational Principles to Assessment and Treatment is available for free on-demand access through the MDS Education Roadmap…. […]
…MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington’s Disease. J Huntingtons Dis. 2015 Sep 29;4(3):279-84. PMID: 26444025 Publications arising from additional work of the working group L Jones,… […]
…in Huntington’s disease. The FDA agreed that the basis for a Biologics License Application for Accelerated Approval of AMT-130 may include: 1. Data from ongoing phase I/II studies compared to… […]